Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
ADI-001 autoimmune clinical development expanded beyond lupus nephritis (LN) to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV), following recent U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearances
IND clearance for ADI-270 for the treatment of patients with relapsed/refractory renal cell carcinoma (RCC)
FDA Fast Track Designation granted for two product candidates
Strong balance sheet with $224.1 million in cash and cash equivalents as of June 30, 2024
REDWOOD CITY, Calif. & BOSTON – August 13, 2024 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2024.
“We believe ADI-001 has best-in-class potential for autoimmune diseases and we are excited about the opportunity to expand ADI-001 clinical development beyond LN to include patients with SLE, SSc and AAV. We have initiated startup activities at multiple clinical sites and expect to begin enrolling patients with LN in our Phase 1 study in the third quarter of 2024,” said Chen Schor, President and Chief Executive Officer at Adicet Bio. “Looking ahead, with the ADI-270 IND cleared for RCC, and Fast Track Designation in hand, we expect to initiate the Phase 1 trial of ADI-270 in patients with RCC, the most common type of kidney cancer, in the fourth quarter of 2024. This progress underscores the unique potential of our gamma delta 1 CAR T cell platform in both autoimmune diseases and solid tumors.”
Second Quarter 2024 and Recent Operational Highlights:
Autoimmune diseases
Hematologic malignancies and solid tumor indications
Financial Results for Second Quarter 2024:
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: preclinical and clinical development of Adicet’s product candidates, including future plans or expectations for ADI-001 and ADI-270, including the potential safety, durability, tolerability and efficacy of these product candidates as well as their potential promising profiles; the potential for ADI-001 to be best-in-class for autoimmune diseases; the progress, timing and success of the Company’s ongoing and planned Phase 1 clinical trials of ADI-001 in autoimmune diseases and cancer, including expectations for site activation, enrollment and data readouts; the Company’s clinical trial of ADI-270 in metastatic/advanced ccRCC, including expectations for site
enrollment and data readouts; and expectations regarding the Company’s uses of capital, expenses and financial results, including the expected cash runway.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet’s business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet’s ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Adicet’s most recent quarterly report on Form 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC), as well as discussions of potential risks, uncertainties, and other important factors in Adicet’s other filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
ADICET BIO, INC.
Consolidated Statements of Operations Information
(in thousands, except share and per share amounts)
(Unaudited)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
25,901 |
|
|
|
28,362 |
|
|
|
49,797 |
|
|
|
55,118 |
|
General and administrative |
|
|
6,948 |
|
|
|
6,528 |
|
|
|
13,922 |
|
|
|
13,093 |
|
Total operating expenses |
|
|
32,849 |
|
|
|
34,890 |
|
|
|
63,719 |
|
|
|
68,211 |
|
Loss from operations |
|
|
(32,849 |
) |
|
|
(34,890 |
) |
|
|
(63,719 |
) |
|
|
(68,211 |
) |
Interest income |
|
|
2,999 |
|
|
|
2,615 |
|
|
|
5,917 |
|
|
|
5,279 |
|
Interest expense |
|
|
— |
|
|
|
(4 |
) |
|
|
(2 |
) |
|
|
(23 |
) |
Other expense, net |
|
|
(51 |
) |
|
|
(124 |
) |
|
|
(113 |
) |
|
|
(329 |
) |
Loss before income tax provision |
|
|
(29,901 |
) |
|
|
(32,403 |
) |
|
|
(57,917 |
) |
|
|
(63,284 |
) |
Income tax provision |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net loss |
|
$ |
(29,901 |
) |
|
$ |
(32,403 |
) |
|
$ |
(57,917 |
) |
|
$ |
(63,284 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.33 |
) |
|
$ |
(0.75 |
) |
|
$ |
(0.68 |
) |
|
$ |
(1.47 |
) |
Weighted-average common shares used in computing net loss per share, basic and diluted |
|
|
90,632,045 |
|
|
|
42,957,035 |
|
|
|
84,848,146 |
|
|
|
42,957,242 |
|
ADICET BIO, INC.
Consolidated Balance Sheets Information
(in thousands)
(Unaudited)
|
|
June 30, |
December 31, |
|
||||
|
|
2024 |
|
|
2023 |
|
||
Cash and cash equivalents |
|
$ |
224,069 |
|
|
$ |
159,711 |
|
Working capital |
|
|
210,449 |
|
|
|
142,985 |
|
Total assets |
|
|
268,842 |
|
|
|
207,295 |
|
Accumulated deficit |
|
|
(438,689 |
) |
|
|
(380,772 |
) |
Total stockholders’ equity |
|
|
235,111 |
|
|
|
170,175 |
|